These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 1674586)
1. Dopamine receptor reappearance after irreversible receptor blockade: effect of chronic estradiol treatment of ovariectomized rats. Lévesque D; Di Paolo T Mol Pharmacol; 1991 May; 39(5):659-65. PubMed ID: 1674586 [TBL] [Abstract][Full Text] [Related]
2. Effect of chronic estradiol treatment on brain dopamine receptor reappearance after irreversible blockade: an autoradiographic study. Morissette M; Lévesque D; Di Paolo T Mol Pharmacol; 1992 Sep; 42(3):480-8. PubMed ID: 1357544 [TBL] [Abstract][Full Text] [Related]
3. Day/night differences in D1 but not D2 DA receptor protection from EEDQ denaturation in rats treated with continuous cocaine. Burger LY; Martin-Iverson MT Synapse; 1993 Jan; 13(1):20-9. PubMed ID: 8093985 [TBL] [Abstract][Full Text] [Related]
4. N-(p-isothiocyanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain. Xu SX; Hatada Y; Black LE; Creese I; Sibley DR J Pharmacol Exp Ther; 1991 May; 257(2):608-15. PubMed ID: 1674530 [TBL] [Abstract][Full Text] [Related]
5. Inactivation of D1 and D2 dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by neuroleptics. Meller E; Bohmaker K; Goldstein M; Friedhoff AJ J Pharmacol Exp Ther; 1985 Jun; 233(3):656-62. PubMed ID: 2861276 [TBL] [Abstract][Full Text] [Related]
6. Chronic treatment with (-)-stepholidine alters density and turnover of D1 and D2 receptors in striatum. Zou LL; Cai ST; Jin GZ Zhongguo Yao Li Xue Bao; 1996 Nov; 17(6):485-9. PubMed ID: 9863137 [TBL] [Abstract][Full Text] [Related]
7. Effect of desipramine during infancy and preweanling on dorsal striatal dopamine D1 and D2 receptor binding in adolescence in the rat. Hilakivi I; Rinne J; Marjamäki P Pol J Pharmacol; 1999; 51(4):311-6. PubMed ID: 10540962 [TBL] [Abstract][Full Text] [Related]
8. Differential modification of striatal D1 dopamine receptors and effector moieties by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo and in vitro. Hess EJ; Battaglia G; Norman AB; Creese I Mol Pharmacol; 1987 Jan; 31(1):50-7. PubMed ID: 3100940 [TBL] [Abstract][Full Text] [Related]
9. Receptor reserve for D2 dopaminergic inhibition of prolactin release in vivo and in vitro. Meller E; Puza T; Miller JC; Friedhoff AJ; Schweitzer JW J Pharmacol Exp Ther; 1991 May; 257(2):668-75. PubMed ID: 1674531 [TBL] [Abstract][Full Text] [Related]
10. Effect of mesulergine on prolactin secretion and dopamine D2 receptors-adaptive changes in diethylstilbestrol-induced hyperplasia of the rat anterior pituitary. Pisarek H; Stepien H; Pawlikowski M Endocr Regul; 1992 Mar; 26(1):17-22. PubMed ID: 1421203 [TBL] [Abstract][Full Text] [Related]
11. Anatomical localization of SKF-38393-induced behaviors in rats using the irreversible monoamine receptor antagonist EEDQ. Neisewander JL; Ong A; McGonigle P Synapse; 1995 Feb; 19(2):134-43. PubMed ID: 7725242 [TBL] [Abstract][Full Text] [Related]
12. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists. Giorgi O; Biggio G Brain Res; 1990 Nov; 533(1):53-9. PubMed ID: 1982234 [TBL] [Abstract][Full Text] [Related]
13. Age-dependent differences in the rate of recovery of striatal dopamine D1 and D2 receptors after inactivation with EEDQ. Crawford CA; Rowlett JK; McDougall SA; Bardo MT Eur J Pharmacol; 1994 Feb; 252(2):225-31. PubMed ID: 8157063 [TBL] [Abstract][Full Text] [Related]
14. Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Meller E; Bohmaker K; Namba Y; Friedhoff AJ; Goldstein M Mol Pharmacol; 1987 Jun; 31(6):592-8. PubMed ID: 2885734 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary. Enjalbert A; Bockaert J Mol Pharmacol; 1983 May; 23(3):576-84. PubMed ID: 6306429 [TBL] [Abstract][Full Text] [Related]
16. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation. Hess EJ; Albers LJ; Le H; Creese I J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223 [TBL] [Abstract][Full Text] [Related]
18. Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors. Hess EJ; Norman AB; Creese I J Neurosci; 1988 Jul; 8(7):2361-70. PubMed ID: 2907912 [TBL] [Abstract][Full Text] [Related]
19. [Direct effect of estradiol on the number of dopaminergic receptors in the anterior pituitary, in ovariectomized rats]. Pasqualini C; Kerdelhue B C R Acad Sci III; 1985; 300(17):637-42. PubMed ID: 3939292 [TBL] [Abstract][Full Text] [Related]
20. Chronic uridine treatment reduces the level of [3H]spiperone-labelled dopamine receptors and enhances their turnover rate in striatum of young rats: relationship to dopamine-dependent behaviours. Farabegoli C; Merlo Pich E; Cimino M; Agnati LF; Fuxe K Acta Physiol Scand; 1988 Feb; 132(2):209-16. PubMed ID: 2906500 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]